John H. Burbank III Portfolio
Invests via Passport Capital LLC | Managed by John H. Burbank III
Invests via Passport Capital LLC
Managed by John H. Burbank III
Automatically Tracked
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Investment Philosophy & Strategy
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
110.48%
Gain +1.6%
Monthly
2.9%
Yearly
41%
Drawdown
52.02%
$17.16B
Equity
Holdings
$17.16B
Investment
$12.43B
$28.96B
Profit +$212.57M
Realized
$24.23B
Unrealized
$4.73B
Dividends
$50.37M
Goals
Avg. 56.5% completed goals
Yearly
Gain > 8% 2026
Yearly
Loss < $300M 2026
Yearly
Loss < 20% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
1.6%
Profit
$212.57M
Win %
63%
This Week
Compared To Last Week
Gain
-3.89%
Profit
-$693.61M
Win %
63%
This Month
Compared to last month
Gain
-8.38%
Profit
-$1.57B
Win %
63%
This Year
Compared to last year
Gain
-1.08%
Profit
-$191.82M
Win %
61%
VSTM Verastem Inc.
+20.75%
+$4M 
TCRX TScan Therapeutics Inc.
+11.44%
+$67,113.49 
NGNE Neurogene Inc.
+8.57%
+$1.88M 
EIKN Eikon Therapeutics, Inc.
+8.35%
+$324,999.67 
LBRX LB Pharmaceuticals Inc.
+7.66%
+$520,580 
SGMT Sagimet Biosciences Inc.
+7.42%
+$533,677.76 
TRDA Entrada Therapeutics Inc.
+6.92%
+$1.6M 
VRDN Viridian Therapeutics Inc.
+6.58%
+$2.88M 
CTMX CytomX Therapeutics Inc.
+6.5%
+$721,494.77 
TSHA Taysha Gene Therapies Inc.
+5.84%
+$820,974.98 
KOD Kodiak Sciences Inc.
+5.61%
+$90.63M 
DSGN Design Therapeutics, Inc.
+4.78%
+$1.25M 
FTH Faeth Therapeutics, Inc.
+4.55%
+$1.17M 
NRIX Nurix Therapeutics Inc.
+4.52%
+$4.98M 
SANA Sana Biotechnology, Inc.
+4.51%
+$32,600.72 
AVLN Avalyn Pharma Inc.
+4.24%
+$351,750 
RAPP Rapport Therapeutics Inc.
+3.98%
+$1.74M 
STOK Stoke Therapeutics Inc.
+3.87%
+$3M 
PRLD Prelude Therapeutics Incorporated
+3.71%
+$1.21M 
PRAX Praxis Precision Medicines Inc.
+3.65%
+$15.28M 
ALMS Alumis Inc.
+3.55%
+$432,687.5 
MPLT MapLight Therapeutics, Inc.
+3.46%
+$98,470.35 
REPL Replimune Group Inc.
+3.29%
+$4.14M 
IRON Disc Medicine Inc.
+3.17%
+$618,892.89 
CLDX Celldex Therapeutics Inc.
+2.73%
+$898,784.36 
MIRM Mirum Pharmaceuticals Inc.
+2.71%
+$967,765.75 
DNLI Denali Therapeutics Inc.
+2.63%
+$1.76M 
AVTX Avalo Therapeutics Inc.
+2.45%
+$159,500 
KNSA Kiniksa Pharmaceuticals International, plc
+2.33%
+$5.22M 
JBIO Jade Biosciences Inc.
+2.33%
+$385,861.59 
ACAD Acadia Pharmaceuticals Inc.
+2.26%
+$18.67M 
DBVT Dbv Technologies S.A. Sponsored ADR
+2.25%
+$292,285 
IONS Ionis Pharmaceuticals, Inc.
+2.2%
+$1.92M 
EWTX Edgewise Therapeutics, Inc.
+2.19%
+$3M 
XENE Xenon Pharmaceuticals Inc.
+2.18%
+$273,953.92 
XNCR Xencor Inc.
+2.01%
+$517,989.82 
RYTM Rhythm Pharmaceuticals Inc.
+1.96%
+$9.5M 
TYRA Tyra Biosciences, Inc.
+1.87%
+$3,712.45 
EVMN Evommune, Inc.
+1.82%
+$88,975.95 
ALGS Aligos Therapeutics Inc.
+1.72%
+$7,474.95 
INCY Incyte Corporation
+1.65%
+$56.45M 
RLAY Relay Therapeutics Inc.
+1.62%
+$782,453.53 
BNTX BioNTech SE
+1.57%
+$166,442.77 
VTVT vTv Therapeutics Inc.
+1.49%
+$60,808.74 
BCYC Bicycle Therapeutics plc American Depositary Receipt
+1.44%
+$548,621.99 
GLUE Monte Rosa Therapeutics, Inc.
+1.42%
+$608,403.04 
ELVN Enliven Therapeutics, Inc.
+1.37%
+$488,803.14 
WVE Wave Life Sciences Ltd.
+1.13%
+$28,792.33 
NTLA Intellia Therapeutics Inc.
+1.09%
+$116,279 
CYTK Cytokinetics, Incorporated
+1.04%
+$139,436.22 
TECX Tectonic Therapeutic Inc.
+1.02%
+$130,248.97 
ALKS Alkermes plc
+1%
+$3.9M 
GPCR Structure Therapeutics Inc.
+0.96%
+$300,831.09 
SMMT Summit Therapeutics Inc.
+0.96%
+$4.75M 
IMTX Immatics N.V.
+0.93%
+$618,056.72 
CERS Cerus Corporation
+0.89%
+$127,908.62 
ROIV Roivant Sciences Ltd
+0.89%
+$1.42M 
ABCL AbCellera Biologics Inc.
+0.85%
+$3.47M 
GENB Generate Biomedicines, Inc.
+0.8%
+$142,360.2 
CELC Celcuity Inc.
+0.68%
+$3.21M 
DYN Dyne Therapeutics Inc.
+0.67%
+$81,344.9 
RCUS Arcus Biosciences Inc.
+0.62%
+$118,274.24 
KYMR Kymera Therapeutics Inc.
+0.4%
+$3.72M 
INSM Insmed Inc.
+0.38%
+$3.25M 
IMNM Immunome Inc.
+0.35%
+$3,318.36 
BEIGF BeiGene Ltd.
0%
$0 
CRNX Crinetics Pharmaceuticals Inc.
0%
$0 
SKYE Skye Bioscience Inc.
0%
$0 1510
15102KAA8
0%
$0 
SRZNW Surrozen Inc.
-60.53%
-$1,916.67 
AKTS Akoustis Technologies Inc.
-3.45%
-$567,421.89 
PBLS Parabilis Medicines, Inc.
-2.57%
-$332,500 
TARA Protara Therapeutics Inc.
-2.02%
-$48,580.7 
DNTH Dianthus Therapeutics Inc.
-1.95%
-$1.24M 
RVMD Revolution Medicines Inc.
-1.6%
-$35.47M 
GRAL Grail, Inc.
-1.57%
-$8.86M 
SION Sionna Therapeutics Inc.
-1.47%
-$24,000 
IMVT Immunovant Inc.
-1.33%
-$2.01M 
SERA Sera Prognostics Inc.
-1.11%
-$125,908.09 
ARWR Arrowhead Pharmaceuticals Inc.
-0.91%
-$1.06M 
IDYA Ideaya Biosciences Inc.
-0.58%
-$976,955.85 
MDGL Madrigal Pharmaceuticals, Inc.
-0.33%
-$3.24M 
ABSI Absci Corporation
-0.29%
-$53,370.07 
TNGX Tango Therapeutics Inc.
-0.04%
-$3,333.33 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 3681 | Longs Won 1882/3681 51% | Profit Factor 4.2 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $79.81M |
| Average Win $20.2M | Best Trade (Sep 30) $2.4B | Sharpe Ratio -23.76 |
| Average Loss -$5.03M | Worst Trade (Oct 14) -$807.89M | Z-Score -7.03 (100%) |
| Commissions $0 | Avg. Trade Length 2y 2m 2w 1d | Expectancy $7.87M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 1.16% |
| Consecutive Losing Trades | 3,413 | 3,072 | 2,730 | 2,389 | 2,048 | 1,706 | 1,365 | 1,024 | 683 | 341 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 1510 15102KAA8 | 30.75M | $40.91M | $40.91M | - | - | - | 0.0 |
| ABCL AbCellera Biologics Inc. | 33.01M | $543.36M | $411.83M | - | -$131.53M | -24.21% | +0.849% |
| ABSI Absci Corporation | 2.13M | $7.45M | $18.6M | - | $11.15M | 149.71% | -0.286% |
| ACAD Acadia Pharmaceuticals Inc. | 42.91M | $676.97M | $844.74M | - | $167.77M | 24.78% | +2.26% |
| AKTS Akoustis Technologies Inc. | 996,351 | $17.82M | $15.86M | - | -$1.96M | -11.01% | -3.454% |
| ALGS Aligos Therapeutics Inc. | 83,055 | $719,256 | $441,852.6 | - | -$277,403.4 | -38.57% | +1.721% |
| ALKS Alkermes plc | 10.01M | $270.05M | $395.18M | - | $125.14M | 46.34% | +0.998% |
| ALMS Alumis Inc. | 2.01M | $30.69M | $12.63M | - | -$18.07M | -58.86% | +3.548% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.99M | $70.7M | $115.26M | - | $44.56M | 63.03% | -0.908% |
| AVLN Avalyn Pharma Inc. | 350,000 | $10.14M | $8.64M | - | -$1.5M | -14.79% | +4.242% |
| AVTX Avalo Therapeutics Inc. | 550,000 | $10.16M | $6.67M | - | -$3.49M | -34.36% | +2.449% |
| BCYC Bicycle Therapeutics plc American Depositary Receipt | 10.89M | $226.24M | $38.76M | - | -$187.49M | -82.87% | +1.436% |
| BEIGF BeiGene Ltd. | 8.8M | $1.57B | $193.16M | - | -$1.38B | -87.71% | 0.0 |
| BNTX BioNTech SE | 119,743 | $12.75M | $10.78M | - | -$1.97M | -15.42% | +1.568% |
| CELC Celcuity Inc. | 7.92M | $196.34M | $477.36M | - | $281.02M | 143.13% | +0.676% |
| CERS Cerus Corporation | 6.4M | $22.12M | $14.45M | - | -$7.67M | -34.66% | +0.893% |
| CLDX Celldex Therapeutics Inc. | 1.18M | $37.57M | $33.82M | - | -$3.75M | -9.97% | +2.73% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.35M | $97.29M | $199.76M | - | $102.47M | 105.32% | 0.0 |
| CTMX CytomX Therapeutics Inc. | 4.98M | $13.76M | $11.82M | - | -$1.94M | -14.13% | +6.502% |
| CYTK Cytokinetics, Incorporated | 211,267 | $18M | $13.54M | - | -$4.46M | -24.77% | +1.041% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for John H. Burbank III?
The largest contributions to the portfolio's profits come from the following stocks: SGEN - $10.15B, 45337CAH5 - $3.03B, PCYC - $2.4B, VPHM - $1.59B, and 795435AC0 - $1.58B. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Dbv Technologies S.A. Sponsored ADR - $294.57M, SUPG - $229.13M, Invitae Corp - $211.7M, Heron Therapeutics Inc - $145.04M, and TRMS - $142.57M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does John H. Burbank III's portfolio generate?
The portfolio generates substantial dividend income, with a total of $50.37M earned over time. The largest contributors to dividend income include AbbVie Inc - $48.49M, Spectrum Pharmaceuticals Inc - $498,054, Gilead Sciences Inc - $429,991.4, Biogen Inc - $366,795, and Ligand Pharmaceuticals Inc - $357,679.55. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are John H. Burbank III's monthly returns?
John H. Burbank III's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can John H. Burbank III's strategy be considered aggressive or moderate?
John H. Burbank III's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow John H. Burbank III's strategy?
John H. Burbank III's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
